Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
NCT05521997
Not Yet Recruiting
Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Advanced Cervical Carcinoma, Cervical Cancer, Cervix Cancer, Cancer of the Cervix
Register for Updates
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder
NCT02202772
Active Not Recruiting
The investigators intend to evaluate the safety and toxicity profile of intravesically administered multidrug regimen of Cabazitaxel, Cisplatin and Gemcitabine in treatment refractory Transitional Cell Carcinoma.The investigators propose to conduct a combined phase I trial to assess the safety, toxicity, and efficacy of a novel multidrug intravesical regimen consisting of Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of BCG resistant non-muscle invasive urothelial carcinoma of the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Columbia University Irving Medical Center - HIP, New York, New York
Conditions: Urothelial Carcinoma of the Urinary Bladder
Register for Updates
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 CtHPV-DNA
NCT05541016
Recruiting
This phase II trial examines the use of blood-based biomarkers is to help inform decision making for treatment and radiation therapy for patients with human papillomavirus (HPV) positive oropharyngeal squamous cell cancers. The standard treatments for head and neck cancers are radiation therapy with chemotherapy or surgery potentially followed by radiation therapy with or without chemotherapy. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving chemotherapy alon... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Register for Updates
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
NCT03574649
Withdrawn
This is a randomized phase 2 study to compare the efficacy of neoadjuvant, consolidation, and adjuvant immunotherapy (NANT NSCLC Combination Immunotherapy; experimental arm) to standard of care (surgery and adjuvant chemotherapy; control arm) in subjects with stage II-IIIa resectable NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California
Conditions: Non Small Cell Lung Cancer
Register for Updates
Heated Intra-peritoneal Chemotherapy with Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients
NCT04213794
Terminated
This early phase I trial studies how well heated intra-peritoneal chemotherapy with doxorubicin and cisplatin work for the treatment of abdominal or pelvic tumors that can be removed by surgery (resectable), does not respond to treatment (refractory), or has come back (recurrent). Heated intra-peritoneal chemotherapy is a procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates... Read More
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
02/18/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm, Recurrent Rhabdomyosarcoma, Recurrent Sarcoma, Refractory Rhabdomyosarcoma, Refractory Sarcoma, Resectable Sarcoma, Recurrent Colon Carcinoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Gastric Carcinoma, Recurrent Liposarcoma, Recurrent Malignant Mesothelioma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Rectal Carcinoma, Refractory Colon Carcinoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Fallopian Tube Carcinoma, Refractory Gastric Carcinoma, Refractory Liposarcoma, Refractory Malignant Mesothelioma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Refractory Rectal Carcinoma, Resectable Liposarcoma, Resectable Malignant Mesothelioma
Register for Updates
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT05659381
Recruiting
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1 every 21 days for 3-4 cycles). Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: City of Hope, Duarte, California +50 locations
Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
Register for Updates
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
NCT00003042
Active Not Recruiting
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This phase II trial is studying how well chemotherapy and stem cell transplantation work in treating patients with stage IIIB breast cancer.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/17/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California
Conditions: Breast Cancer
Register for Updates
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
NCT04620187
Recruiting
This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It will also examine the effectiveness of study drug Ado-trastuzumab (T) emtansine (DM1) on cancer recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: University of Chicago, Chicago, Illinois +11 locations
Conditions: Salivary Gland Cancer, HER2 Gene Mutation
Register for Updates
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
NCT05075980
Recruiting
This clinical trial studies how well intensity modulated proton therapy (IMPT) or intensity modulated X-ray (radiation) therapy (IMRT) works after surgery in treating patients with head and neck cancer. IMPT is a type of radiation therapy that allows for the most accurate application of proton radiation to the tumor and has the potential to reduce treatment-related side effects. IMRT is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Mayo Clinic Hospital in Arizona, Phoenix, Arizona +8 locations
Conditions: Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Metastatic Malignant Neoplasm in the Lymph Nodes, Nasal Cavity Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Carcinoma, Paranasal Sinus Carcinoma, Salivary Gland Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
NCT01898494
Active Not Recruiting
This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy with chemotherapy may kill any tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +57 locations
Conditions: Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
Register for Updates
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
NCT02215265
Active Not Recruiting
The main objectives of the PATHOS study are: To assess whether swallowing function can be improved following transoral resection of HPV-positive OPSCC, by reducing the intensity of adjuvant treatment protocols. The aim is to personalise treatment, based on disease biology (HPV status and pathology findings), to optimise patient outcomes. To demonstrate the non-inferiority of reducing the intensity of adjuvant treatment protocols in terms of overall survival in the reduced intensity treatment a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Board of Trustees of the Leland Stanford Junior University, Redwood City, California +56 locations
Conditions: Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
Register for Updates
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
NCT03976323
Active Not Recruiting
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent clinical review (BICR) and 2. Pembrolizu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Alabama Oncology Bruno Cancer Center ( Site 0001), Birmingham, Alabama +177 locations
Conditions: Carcinoma, Nonsquamous Non-small-cell Lung
Register for Updates